Investigation of Cognitive Outcomes With Cannabidiol Oral Solution

Summary

This study is being conducted to evaluate the effects of GWP42003-P on cognition in pediatric participants, aged 3 to 10 years, with Lennox-Gastaut Syndrome (LGS).

Timeline

Start

2020-10

Primary completion

2021-12

Completion

2021-12

Outcome

Outcome not reported

Stopped (Enrollment): “The decision to withdraw the study was based on pandemic-related concerns of conducting a Phase IV study requiring multiple clinic visits when medication is commercially available. The study was withdrawn before any participants were recruited.”

Drugs

Indications